{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T06:28:22Z","timestamp":1794119302337,"version":"4.8.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["177966"],"award-info":[{"award-number":["177966"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["287842"],"award-info":[{"award-number":["287842"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000304","name":"Parkinson's UK","doi-asserted-by":"publisher","award":["G0502"],"award-info":[{"award-number":["G0502"]}],"id":[{"id":"10.13039\/501100000304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000304","name":"Parkinson's UK","doi-asserted-by":"publisher","award":["G0914"],"award-info":[{"award-number":["G0914"]}],"id":[{"id":"10.13039\/501100000304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000304","name":"Parkinson's UK","doi-asserted-by":"publisher","award":["G1302"],"award-info":[{"award-number":["G1302"]}],"id":[{"id":"10.13039\/501100000304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014589","name":"Chief Scientist Office, Scottish Government Health and Social Care Directorate","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014589","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000355","name":"Bupa Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000355","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007436","name":"Familjen Erling-Perssons Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007067","name":"Kempestiftelserna","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007067","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002960","name":"V\u00e4sterbotten L\u00e4ns Landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002960","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004257","name":"Helse Vest","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004257","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Objectives:<\/jats:bold> To evaluate the impact of <jats:italic>SNCA<\/jats:italic> polymorphisms originally identified as risk factors for Parkinson's disease (PD) on the clinical presentation and progression of the disease in a large cohort of population-based patients with incident PD.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Four hundred thirty-three patients and 417 controls from three longitudinal cohorts were included in the study. Disease progression was recorded annually for up to 9 years using the Unified Parkinson's Disease Rating Scale (UPDRS) or Mini-Mental State Examination. Genotypes for five variants within the <jats:italic>SNCA<\/jats:italic> locus (rs2870004, rs356182, rs5019538, rs356219, and rs763443) were determined. We studied the association between each variant and disease progression using linear mixed-effects regression models.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The clinical profile of the patients with PD at the point of diagnosis was highly uniform between genotype groups. The rs356219-GG genotype was associated with a higher UPDRS II score than A-allele carriers (\u03b2 = 1.52; 95% confidence interval 0.10\u20132.95; <jats:italic>p<\/jats:italic> = 0.036), but no differences were observed in the rate of progression of the UPDRS II scores. rs356219-GG was also associated with a faster annual change in Mini-Mental State Examination score compared with A-carriers (\u03b2 = 0.03; 95% confidence interval 0.00\u20130.06; <jats:italic>p<\/jats:italic> = 0.043).<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> We show that the known PD-risk variant rs356219 has a minor effect on modifying disease progression, whereas no differences were associated with rs2870004, rs356182, rs5019538, and rs763443. These findings suggest that <jats:italic>SNCA<\/jats:italic> variants associated with PD risk may not be major driving factors to the clinical heterogeneity observed for PD.<\/jats:p>","DOI":"10.3389\/fneur.2020.620585","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T18:41:09Z","timestamp":1612982469000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Association of SNCA Parkinson's Disease Risk Polymorphisms With Disease Progression in Newly Diagnosed Patients"],"prefix":"10.3389","volume":"11","author":[{"given":"Aleksandra A.","family":"Szwedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla Christina","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Ushakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Forsgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole-Bj\u00f8rn","family":"Tysnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl E.","family":"Counsell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angus D.","family":"Macleod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi","family":"Maple-Gr\u00f8dem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/jnc.13691","article-title":"The clinical symptoms of Parkinson's disease","volume":"139","author":"Sveinbjornsdottir","year":"2016","journal-title":"J Neurochem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/jnnp-2018-318337","article-title":"Developing and validating Parkinson's disease subtypes and their motor and cognitive progression","volume":"89","author":"Lawton","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","article-title":"Cognitive decline in Parkinson disease","volume":"13","author":"Aarsland","year":"2017","journal-title":"Nat Rev Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1093\/brain\/awp245","article-title":"The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort","volume":"132","author":"Williams-Gray","year":"2009","journal-title":"Brain."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","article-title":"Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies","volume":"18","author":"Nalls","year":"2019","journal-title":"Lancet Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/ana.25274","article-title":"A comprehensive analysis of SNCA-related genetic risk in sporadic parkinson disease","volume":"84","author":"Pihlstr\u00f8m","year":"2018","journal-title":"Ann Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1002\/mds.27845","article-title":"Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts","volume":"34","author":"Iwaki","year":"2019","journal-title":"Mov Disord."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e348","DOI":"10.1212\/NXG.0000000000000348","article-title":"Genetic risk of Parkinson disease and progression: an analysis of 13 longitudinal cohorts","volume":"5","author":"Iwaki","year":"2019","journal-title":"Neurol Genet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3389\/fnmol.2019.00299","article-title":"Targeting alpha-synuclein as a therapy for Parkinson's disease","volume":"12","author":"Fields","year":"2019","journal-title":"Front Mol Neurosci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/ng.3955","article-title":"A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci","volume":"49","author":"Chang","year":"2017","journal-title":"Nat Genet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/ng.3043","article-title":"Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease","volume":"46","author":"Nalls","year":"2014","journal-title":"Nat Genet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/hmg\/ddw379","article-title":"Genome-wide association study of Parkinson's disease in East Asians","volume":"26","author":"Foo","year":"2016","journal-title":"Hum Mol Genet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1136\/jnnp.2008.168211","article-title":"Incidence of Parkinson's disease in Norway: the Norwegian ParkWest study","volume":"80","author":"Alves","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.parkreldis.2013.01.014","article-title":"Age-, gender-, and socioeconomic status-specific incidence of Parkinson's disease and parkinsonism in northeast Scotland: the PINE study","volume":"19","author":"Caslake","year":"2013","journal-title":"Parkinsonism Relat Disord."},{"key":"B15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/mds.22987","article-title":"Incidence of Parkinson's disease and parkinsonism in northern Sweden: a population-based study","volume":"25","author":"Linder","year":"2010","journal-title":"Mov Disord."},{"key":"B16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology."},{"key":"B17","first-page":"153","article-title":"Unified Parkinson's disease rating scale","volume":"2","author":"Fahn","year":"1987","journal-title":"Recent Dev Parkinsons Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson's disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov Disord."},{"key":"B20","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(10)62345-8","article-title":"Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies","volume":"377","author":"Nalls","year":"2011","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3389\/fnagi.2019.00110","article-title":"Variants in the SNCA locus are associated with the progression of Parkinson's disease","volume":"11","author":"Luo","year":"2019","journal-title":"Front Aging Neurosci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ana.21192","article-title":"Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease","volume":"62","author":"Goris","year":"2007","journal-title":"Ann Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1212\/WNL.0000000000000066","article-title":"Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study","volume":"82","author":"Yarnall","year":"2014","journal-title":"Neurology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3389\/fnagi.2017.00198","article-title":"Variants in SNCA gene are associated with Parkinson's disease risk and cognitive symptoms in a Brazilian sample","volume":"9","author":"Campelo","year":"2017","journal-title":"Front Aging Neurosci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1001\/jamaneurol.2014.1455","article-title":"APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease","volume":"71","author":"Mata","year":"2014","journal-title":"JAMA Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/jnnp-2019-322210","article-title":"A common polymorphism in SNCA is associated with accelerated motor decline in GBA-Parkinson's disease","volume":"91","author":"Stoker","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B27","doi-asserted-by":"publisher","first-page":"209 e1","DOI":"10.1016\/j.neurobiolaging.2015.09.014","article-title":"Variants in GBA, SNCA, and MAPT influence Parkinson disease risk, age at onset, and progression","volume":"37","author":"Davis","year":"2016","journal-title":"Neurobiol Aging."},{"key":"B28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/acn3.371","article-title":"Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype","volume":"4","author":"Cooper","year":"2017","journal-title":"Ann Clin Transl Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.parkreldis.2018.05.027","article-title":"Age-related selection bias in Parkinson's disease research: are we recruiting the right participants?","volume":"55","author":"Macleod","year":"2018","journal-title":"Parkinsonism Relat Disord."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.620585\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T18:41:13Z","timestamp":1612982473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.620585\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,10]]},"references-count":29,"alternative-id":["10.3389\/fneur.2020.620585"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.620585","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,10]]},"article-number":"620585"}}